ROIVANT SCIENCES LTD. Current Liabilities
ROIVANT SCIENCES LTD. (ROIV) had Current Liabilities of $283.60 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $283.60M.
- 2026-03-31: Liabilities, Current $281.24M.
- 2025-12-31: Liabilities, Current $151.96M.
- 2025-09-30: Liabilities, Current $133.86M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $283.60M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $281.24M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $151.96M 10-Q · filed 2026-02-06 |
| 2025-09-30 | $133.86M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $113.87M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $149.41M 10-K · filed 2026-05-20 |
| 2024-12-31 | $141.48M 10-Q · filed 2025-02-10 |
| 2024-09-30 | $556.25M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $215.04M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $266.76M 10-K · filed 2025-05-29 |
| 2023-12-31 | $244.90M 10-Q · filed 2024-02-13 |
| 2023-09-30 | $265.55M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $245.00M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $272.45M 10-K · filed 2024-05-30 |
| 2022-12-31 | $244.25M 10-Q · filed 2023-02-13 |
| 2022-09-30 | $230.74M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $328.92M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $184.37M 10-K · filed 2023-06-28 |
| 2021-12-31 | $160.71M 10-Q · filed 2022-02-14 |
| 2021-09-30 | $303.44M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $209.16M 10-Q · filed 2021-09-21 |
| 2021-03-31 | $218.96M 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |